AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteTIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics.
More Information Supplier PageTIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics.
More Information Supplier PageTIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics.
More Information Supplier PageTicagrelor (AZD6140) is the first reversibly binding oral P2Y(12) receptor antagonist that blocks ADP-induced platelet aggregation.
More Information Supplier PageTiclopidine is an adenosine diphosphate (ADP) receptor inhibitor. It inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen.
More Information Supplier PageTiclopidine is an adenosine diphosphate (ADP) receptor inhibitor. It inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen.
More Information Supplier PageTideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy
More Information Supplier PageTideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy
More Information Supplier PageTideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy
More Information Supplier PageTideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy
More Information Supplier PageTie2 kinase inhibitor is a potent and selective Tie2 inhibitor with IC50 of 0.25 ??M.
More Information Supplier PageTie2 kinase inhibitor is a potent and selective Tie2 inhibitor with IC50 of 0.25 ??M.
More Information Supplier PageTie2 kinase inhibitor is a potent and selective Tie2 inhibitor with IC50 of 0.25 ??M.
More Information Supplier PageTie2 kinase inhibitor is a potent and selective Tie2 inhibitor with IC50 of 0.25 ??M.
More Information Supplier PageTie2 kinase inhibitor is a potent and selective Tie2 inhibitor with IC50 of 0.25 ??M.
More Information Supplier PageTigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation.
More Information Supplier PageTigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation.
More Information Supplier PageTigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation.
More Information Supplier PageTigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation.
More Information Supplier PageTigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation.
More Information Supplier PageTiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
More Information Supplier PageTiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
More Information Supplier PageTiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
More Information Supplier PageTimosaponin B-II is a major active component of Anemarrhena asphodeloides Bunge (Liliaceae, rhizome) that has protective effects against cerebral ischaemic damage.
More Information Supplier PageTimosaponin B-II is a major active component of Anemarrhena asphodeloides Bunge (Liliaceae, rhizome) that has protective effects against cerebral ischaemic damage.
More Information Supplier PageTimosaponin B-II is a major active component of Anemarrhena asphodeloides Bunge (Liliaceae, rhizome) that has protective effects against cerebral ischaemic damage.
More Information Supplier PageTioconazole is an antifungal medication of the imidazole class used to treat infections caused by a fungus or yeast.
More Information Supplier PageTioconazole is an antifungal medication of the imidazole class used to treat infections caused by a fungus or yeast.
More Information Supplier PageTioconazole is an antifungal medication of the imidazole class used to treat infections caused by a fungus or yeast.
More Information Supplier PageTipifarnib (Zarnestra) is a farnesyltransferase inhibitor that inhibits the Ras kinase in a post translational modification step before the kinase pathway becomes hyperactive.
More Information Supplier PageTipifarnib (Zarnestra) is a farnesyltransferase inhibitor that inhibits the Ras kinase in a post translational modification step before the kinase pathway becomes hyperactive.
More Information Supplier PageTipifarnib (Zarnestra) is a farnesyltransferase inhibitor that inhibits the Ras kinase in a post translational modification step before the kinase pathway becomes hyperactive.
More Information Supplier PageTipifarnib (Zarnestra) is a farnesyltransferase inhibitor that inhibits the Ras kinase in a post translational modification step before the kinase pathway becomes hyperactive.
More Information Supplier PageTipifarnib (Zarnestra) is a farnesyltransferase inhibitor that inhibits the Ras kinase in a post translational modification step before the kinase pathway becomes hyperactive.
More Information Supplier PageTipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI).
More Information Supplier PageTipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI).
More Information Supplier PageTipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI).
More Information Supplier PageTipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI).
More Information Supplier PageTiplaxtinin is a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1.
More Information Supplier PageTiplaxtinin is a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1.
More Information Supplier PageTiplaxtinin is a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1.
More Information Supplier PageTipranavir, a nonpeptidic HIV protease inhibitor (NPPI), inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-PI-resistant HIV-1 isolates.
More Information Supplier PageTipranavir, a nonpeptidic HIV protease inhibitor (NPPI), inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-PI-resistant HIV-1 isolates.
More Information Supplier PageTipranavir, a nonpeptidic HIV protease inhibitor (NPPI), inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-PI-resistant HIV-1 isolates.
More Information Supplier PageTirapazamine is a bioreductive, anti-neoplastic, anti-cancer agent that is selectively toxic to cells under hypoxic conditions.
More Information Supplier PageTirapazamine is a bioreductive, anti-neoplastic, anti-cancer agent that is selectively toxic to cells under hypoxic conditions.
More Information Supplier PageTirapazamine is a bioreductive, anti-neoplastic, anti-cancer agent that is selectively toxic to cells under hypoxic conditions.
More Information Supplier PageTirapazamine is a bioreductive, anti-neoplastic, anti-cancer agent that is selectively toxic to cells under hypoxic conditions.
More Information Supplier Page
